At the same time, inhibitors targeting immune checkpoints, including anti‐CTLA‐4, PD‐1, and PD‐L1 antisubstances, have been accepted for treating HCC, but relevant studies have shown that their objective response rate is still very limited. This evidence concerns the gene CD274 and hepatocellular carcinoma.